Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
04 Janeiro 2022 - 12:00PM
Business Wire
Pfizer Inc. (NYSE: PFE) invites investors and the general public
to listen to a webcast of a discussion with Albert Bourla, Chairman
and CEO, at the 40th Annual J.P. Morgan Healthcare Conference on
Monday, January 10, 2022 at 3:00 p.m. Eastern Standard Time.
To view and listen to the webcast, visit our web site at
www.pfizer.com/investors. Information on accessing and registering
for the webcast will be available at www.pfizer.com/investors
beginning today.
The transcript and webcast replay of the discussion will be made
available on our web site at www.pfizer.com/investors within 24
hours after the end of the live discussion and will be accessible
for at least 90 days.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, our
anticipated operating and financial performance, reorganizations,
business plans and prospects; expectations for our product
pipeline, in-line products and product candidates, including
anticipated regulatory submissions, data read-outs, study starts,
approvals, clinical trial results and other developing data,
revenue contribution, growth, performance, timing of exclusivity
and potential benefits; strategic reviews; capital allocation
objectives; dividends and share repurchases; plans for and
prospects of our acquisitions, dispositions and other business
development activities, and our ability to successfully capitalize
on these opportunities; manufacturing and product supply; and our
efforts to respond to COVID-19, including our development of a
vaccine to help prevent COVID-19 and treatment for COVID-19, that
are subject to substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statements. A description of these risks and uncertainties
can be found in Pfizer’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2020 and in its subsequent reports on Form
10-Q, including in the sections thereof captioned “Risk Factors”
and “Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005150/en/
Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226
Investor Contact:
IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024